CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Cortes-Dericks, Lourdes; Schmid, Ralph A.

doi:10.1186/s12931-017-0546-5

Cited by 35 publications

(33 citation statements)

References 126 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD44 can be detected immunohistochemically in mesothelial tissues, confirming the presence of neoplastic cells, and it is more expressed in epithelioid rather than in sarcomatoid histotypes (18). However, it is a more reliable marker to distinguish MPM from pulmonary adenocarcinoma than MPM from MH (18,19). In a study by our group, CD44 expression was low in most (57.7%) mesothelioma samples and only in 11.5% of the MH samples (19).…”

Section: Diagnostic Markers By Ihc or Fishsupporting

confidence: 52%

“…In cancer cells, CD44 interacts with hyaluronan-rich microenvironments modifying cell signaling pathways that trigger the ability of malignant cells to migrate, invade basement membranes and lodge at distant sites of the tumor (17). CD44 can be detected immunohistochemically in mesothelial tissues, confirming the presence of neoplastic cells, and it is more expressed in epithelioid rather than in sarcomatoid histotypes (18). However, it is a more reliable marker to distinguish MPM from pulmonary adenocarcinoma than MPM from MH (18,19).…”

Section: Diagnostic Markers By Ihc or Fishmentioning

confidence: 99%

“…In tumors, HA binding to CD44 evokes an interaction of CD44 with signaling receptors, and high levels of HA in PEs of MPM patients compared with non-mesothelioma fluids have suggested its diagnostic value (18). Analysis of HA expression in pleural fluids could increase sensitivity of cytological diagnosis from 48% to 71-91% (48); however, its high levels do not appear specific for MPM because they can additionally occur in other malignant or benign reactive diseases, and low levels do not exclude MPM (49).…”

Section: Soluble Markers In Pesmentioning

confidence: 99%

See 2 more Smart Citations

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Bruno¹,

Alì²,

Fontanini³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure. Histopathological analysis of pleural tissues is the gold standard for diagnosis; however, it can be difficult to differentiate malignant from benign pleural lesions. The purpose of this review is to describe the most important biomarkers and new diagnostic tools suggested for this differential diagnosis. There are many studies concerning the separation between MPM and benign pleural proliferations from both pleural tissues or effusions; most of them are based on the evaluation of one or few biomarkers by immunohistochemistry (IHC) or enzyme-linked immunosorbent assays (ELISAs), whereas others focused on the identification of MPM signatures given by microRNA (miRNA) or gene expression profiles as well as on the combination of molecular data and classification algorithms. None of the reported biomarkers showed adequate diagnostic accuracy, except for p16 [evaluated by fluorescent in situ hybridization (FISH)] and BAP1 (evaluated by IHC), both biomarkers are recommended by the International Mesothelioma Interest Group guidelines for histological and cytological diagnosis. BAP1 and p16 showed a specificity of 100% in discerning malignant from benign lesions because they are exclusively unexpressed or deleted in MPM. However, their sensitivity, even when used together, is not completely sufficient, and absence of their alterations cannot confirm the benign nature of the lesion. Recently, the availability of new techniques and increasing knowledge regarding MPM genetics led to the definition of some molecular panels, including genes or miRNAs specifically deregulated in MPM, that are extremely valuable for differential diagnosis. Moreover, the development of classification algorithms is facilitating the application of molecular data for clinical practice. Data regarding new diagnostic tools and MPM signatures are absolutely promising; however, before their application in clinical practice, a prospective validation is necessary, as these approaches could surely improve the differential diagnosis between malignant and benign pleural lesions.

show abstract

Section: Diagnostic Markers By Ihc or Fishsupporting

confidence: 52%

Section: Diagnostic Markers By Ihc or Fishmentioning

confidence: 99%

Section: Soluble Markers In Pesmentioning

confidence: 99%

See 1 more Smart Citation

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Bruno¹,

Alì²,

Fontanini³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…The inhibition of HA synthesis/signaling or the depletion of HA in tumor stroma may be a promising therapeutic approach to fight against PDAC progression (112). HA was also reported to facilitate cell proliferation and invasiveness in malignant pleural mesothelioma (163) and in melanoma (164) and may be used as a biomarker for early diagnosis and management of these diseases (163)(164)(165).…”

Section: Proteoglycansmentioning

confidence: 99%

Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) is composed of various cell types embedded in an altered extracellular matrix (ECM). ECM not only serves as a support for tumor cell but also regulates cell-cell or cell-matrix cross-talks. Alterations in ECM may be induced by hypoxia and acidosis, by oxygen free radicals generated by infiltrating inflammatory cells or by tumor-or stromal cell-secreted proteases. A poorer diagnosis for patients is often associated with ECM alterations. Tumor ECM proteome, also named cancer matrisome, is strongly altered, and different ECM protein signatures may be defined to serve as prognostic biomarkers. Collagen network reorganization facilitates tumor cell invasion. Proteoglycan expression and location are modified in the TME and affect cell invasion and metastatic dissemination. ECM macromolecule degradation by proteases may induce the release of angiogenic growth factors but also the release of proteoglycan-derived or ECM protein fragments, named matrikines or matricryptins. This review will focus on current knowledge and new insights in ECM alterations, degradation, and reticulation through cross-linking enzymes and on the role of ECM fragments in the control of cancer progression and their potential use as biomarkers in cancer diagnosis and prognosis.

show abstract

“…HA is a prominent component of the microenvironment in most malignant tumors, and CD44 is the major receptor for HA. The binding of HA to the extracellular domain of CD44 promotes its interaction with certain cytoskeletal proteins [20,21] and stimulates a variety of tumor cell-speci ic functions and tumor progression [22]. Therefore, HA is used for targeting tumor cells that overexpress CD44 on the cell surface.…”

Section: Polyplexes and Lipoplexes Modifi Ed With Hyaluronic Acidmentioning

confidence: 99%

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Hattori¹

2017

J Genet Med Gene Ther

View full text Add to dashboard Cite

Nucleic acid-based therapy has become an increasingly important strategy for treating a variety of human diseases. In systemic therapy, a therapeutic gene must be delivered effi ciently to its target tissues without side effects. To deliver a therapeutic gene such as plasmid DNA (pDNA) or small interfering RNA (siRNA) to target tissues by systemic administration, cationic carriers such as cationic liposomes and polymers have been commonly used as a non-viral vector. However, the binary complex of therapeutic gene and cationic carrier must be stabilized in the blood circulation by avoiding agglutination with blood components, because electrostatic interactions between positively charged complexes and negatively charged erythrocytes can cause agglutination, and the agglutinates contribute to high entrapment of the therapeutic genes in the highly extended lung capillaries. One promising approach for overcoming this problem is modifi cation of the surface of cationic complexes with anionic biodegradable polymers such as hyaluronic acid, chondroitin sulfate, or polyglutamic acid. As another approach, we recently developed a sequential injection method of anionic polymer and cationic liposome/therapeutic gene complex (cationic lipoplex) for delivery of a therapeutic gene into the liver or liver metastasis. In this review, we describe recent advances in the delivery of therapeutic genes by lipid-and polymerbased carrier systems using anionic polymers.

show abstract

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Cited by 35 publications

References 126 publications

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Contact Info

Product

Resources

About